Collectively, in ALL—characterized by negligible FSP1—GPX4 inhibition alone is sufficient to trigger ferroptosis, whereas dual targeting of GPX4 and FSP1 represents a rational strategy for high-FSP1 AML. Here, GPX4 is linked to acute lymphoblastic leukemia.